Britain Secures Tariff-Free Drug Deal with U.S.

The United Kingdom has successfully negotiated a pharmaceutical partnership with the United States, which assures tariff-free access for British medicines to the U.S. market. The agreement, a segment of a broader trade accord, pledges a zero tariff for three years on British pharmaceuticals entering the U.S.

British Business and Trade Minister Peter Kyle highlighted that this partnership reinforces the U.S.-British economic ties and will support Britain's strong pharmaceutical industry while securing high-skilled jobs. The U.K. claims this makes it the only nation with such advantages.

The deal also includes protective measures against potential tariffs on medical technology exports and promises mitigation under the proposed U.S. drug pricing policy. Major British pharmaceutical companies, including AstraZeneca and GSK, have welcomed this agreement for the stability it brings.